PCR & NGS Based Diagnostic Testing Market Size By Product (Consumables, Equipment, Labware), By End-use (Hospitals and Clinics, Diagnostic Centers, Ambulatory Settings), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027

Published Date: May 2021  |  Report ID: GMI5057  |  Authors: Sumant Ugalmugale, Rupali Swain

Report Format: PDF   |   Pages: 136   |   Base Year: 2020




Summary Table of Contents Industry Coverage Methodology

Industry trends

PCR and NGS Based Diagnostic Testing Market size exceeded USD 21.5 billion in 2020 and is estimated to grow at a CAGR of over -0.2% from 2021 to 2027. Rising importance of PCR & NGS based diagnostic testing in detection of viruses and other infectious diseases will accelerate the market growth.
 

PCR & NGS Based Diagnostic Testing Market Overview

Get more details on this report - Request Free Sample PDF
 

High risk of infection in geriatric population is one of the major factors responsible for the increased number of PCR & NGS based diagnostic testing. Growing usage of next generation sequencing techniques in the pharma and biopharma industry has boosted the sales of the equipment and consumables across the world. Additionally, increasing R&D activities in diagnostics industry in developed economies will creating growth opportunities for the PCR & NGS based diagnostic testing market.
 

PCR & NGS based diagnostic testing, as the name suggests are diagnostic tests based on technologies like polymerase chain reaction, and next generation sequencing. These tests are carried out to detect or confirm a presence of disease and to monitor its progression. PCR & NGS based diagnostic tests also include the use of diagnostic tools and equipment to analyse the samples and get accurate results. The advancement in technology over the years have aided in developing novel tests to determine the new or rare disease conditions.
 

Many companies and institutions are constantly involved in developing the advanced PCR and NGS technologies and improving the existing technologies for better disease diagnosis. The COVID-19 pandemic has impacted the PCR & NGS based diagnostic testing market positively. There has been tremendous rise in the number of PCR based tests for the detection of COVID-19. The demand for detection kits and consumables has surged all across the world. To cater to the demand, top companies like Thermo Fisher Scientific have increased their production for PCR based detection kits, and number of new companies have entered the market to manufacture diagnostic consumables. On the other hand, high cost of PCR & NGS based diagnostic testing can be a major factor hindering the industry growth

 

Rising importance of PCR & NGS based diagnostic tests for virus detection will propel the product demand

In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was detected causing COVID-19. It was first originated in Wuhan, China. But soon it spread across the world and was officially declared as pandemic. The effect of COVID-19 is immensely catastrophic and pushing the healthcare system of even the developed markets such as the U.S. and Italy to the brink of collapse. Detection kits are considered as one of the key factors for tackling the spread of COVID-19 across the globe. Various research institutes and universities are adopting advanced technologies to develop advance testing kits. Medical device manufacturers have surged the development and production of COVID-19 detection kits, thus fostering the PCR & NGS based diagnostic testing market expansion.
 

Several companies are using their technologies and racing against time to develop PCR & NGS based diagnostic testing kits for faster detection of COVID-19 cases. GenMarkDx used its eSensor technology to minimize the risk of sample contamination. Recently, the company received Emergency Use Authorization (EUA) from FDA for its novel coronavirus diagnostic test ePlex SARS-CoV-2. XCR Diagnostics, a U.S. based startup offered their patented technology Xtreme Chain Reaction in point of care solutions. The increased importance of PCR & NGS based diagnostic testing and its high usage for virus detection during the pandemic will impel the PCR and NGS based diagnostic testing market demand.
 

Increasing usage of consumables in PCR & NGS based diagnostic testing will result in the market progression

The consumables segment in the PCR & NGS based diagnostic testing market accounted for USD 18.8 billion in 2020. Consumable segment includes the disposable products that are used in the PCR & NGS based diagnostic testing. This includes diagnostic kits (inclusive of COVID-19 detection kits), reagents, tips, plates, plastic cases etc. As these products are non-reusable, there is repetitive requirement of consumables in diagnostic tests. High demand and usage of consumables products is the prominent reason for its high industry size.
 

Growing number of diagnostic centers will offer significant market revenue opportunities

PCR & NGS Based Diagnostic Testing Market Size

Get more details on this report - Request Free Sample PDF
 

The diagnostic centers segment captured 36% of the PCR & NGS based diagnostic testing market share in 2020. The diagnostic centers are the special facilities with extensive variety of diagnostic testing procedures including PCR & NGS based diagnostic testing. Besides, the diagnostic centers have high testing capacity along with high accuracy due to advanced technology and apt medical infrastructure. All these factors are driving the segment growth for diagnostic centers in the short term. However, with reduction in COVID cases and tests, the market is expected to show negative growth by the end of the forecast period.
 

Increased number of diagnostic tests in North America region will accelerate the market value

North America PCR & NGS Based Diagnostic Testing Market

Get more details on this report - Request Free Sample PDF
 

The U.S. dominated the North America PCR & NGS based diagnostic testing market and accounted for over USD 5.4 billion in 2020. Also, the North America market is projected to showcase 1.2% growth rate through 2027 owing to the rising sales of consumables such as test kits, sample collectors and equipment like thermal cyclers. There has been sudden rise in the number of diagnostic tests since the outbreak of a pandemic. Moreover, increase in the diagnostic centers, ambulatory settings and makeshift facilities during the pandemic has resulted in high demand for PCR & NGS based diagnostic testing equipment and consumable materials supporting the industry expansion. In addition, presence of major market players such as Qiagen, Agilent, and Thermo Fisher Scientific among others is aiding the growth of PCR and NGS based diagnostic testing market in the region.
 

Rising number of participants involved in developing novel NGS and PCR based diagnostic products are pushing the market growth

Some of the key companies functioning in the PCR & NGS based diagnostic testing market include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Eppendorf AG, Fluotics, Hamilton Company, Illumina, Inc., Integra LifeScience Holdings Corporation, MGI Tech Co., Ltd, Mascon, Inc., Qiagen Inc, Roche Diagnostics, Thermo Fisher Scientific, Thomas Scientific (The Carlyle Group), and VWR International (Avantor, Inc.). These industry leaders have been undergoing strategic developments to sustain the market competition and capture sizable revenue share in the testing industry.
 

Some of the recent industry developments:

  • In April 2021, Illumina and Kartos Therapeutics announced a partnership to develop an NGS-based TP53 companion diagnostic. This partnership is aimed at expanding the diagnostic offerings in oncology.
     
  • In March 2020, Qiagen released QIAstat-Dx test kit to the United States as a first syndromic test for detection of SARS-CoV-2 coronavirus. This novel panel contains assays targeting two genes used to widely detect SARS-CoV-2. This strategy will enhance the overall revenue and brand image of the firm in the industry
     

The PCR & NGS based diagnostic testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Market, By Product, 2016-2027 (USD Million)

  • Consumables
  • Equipment
  • Labware

Market, By End-use, 2016-2027 (USD Million)

  • Hospital and clinics
  • Diagnostic centers
  • Ambulatory settings
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
       

Frequently Asked Questions (FAQ) :

The industry share of PCR & NGS based diagnostic testing was valued at USD 21.5 billion in 2020 and will expand with higher usage in the detection of viruses and other infectious diseases.
The industry revenue from consumable products had reached USD 18.8 billion in 2020 and will grow in the coming years owing to the increasing adoption of disposable products in the PCR and NGS based diagnostic testing.
Diagnostic centers accounted for over 36% of the PCR & NGS based diagnostic testing market share in 2020 and will observe growth due to the presence of latest technologies and apt medical infrastructure.
North America PCR & NGS based diagnostic testing market size is pegged to strike a 1.2% growth rate up to 2027 driven by the rising sales of consumables in the region.

Premium Report Details

  • Published Date: May 2021
  • Pages: 136
  • Tables: 115
  • Charts / Figures: 19
  • Companies covered: 14
  • Countries covered: 15

Get a report that explains COVID-19 impact on this market

Buy NowImmediate delivery available

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X